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What’s already known about this topic:  
- Linear morphoea (LM) is a rare connective tissue disorder 
- The underlying mechanism responsible for the fibrosis of LM is unknown. 
What does this study add? 
- LM fibroblasts from diseased skin possess a persistent, identifiable cell phenotype 
- LM fibroblasts display increased cell growth, and migration, and reduced response to TGF-
β1. 
What is the translational message: 
- Cell-intrinsic changes in the LM fibroblast secretome lead to changes observed in the 
disease, 
- Secretome modulation could be a viable therapeutic approach in the treatment of LM. 
Manuscript  
ABSTRACT 
Background: Linear morphoea (LM) is a rare connective tissue disorder characterised by a line of 
thickened skin and subcutaneous tissue and can also affect the underlying muscle and bone. Little is 
known about disease aetiology, with treatment currently limited to immune suppression, and 
disease recurrence post-treatment is common.  
Objective: To uncover new therapeutic avenues, the cell intrinsic changes in LM fibroblasts 
compared to site-matched controls was characterised.  
Methods: We grew fibroblasts from site matched affected and unaffected regions from 5 linear 
morphoea patients, we subjected them to gene expression analysis and investigation of SMAD 
signalling. 
Results: Fibroblasts from LM lesions showed increased migration, proliferation, altered collagen 
processing, as well as abnormally high basal levels of phosphorylated SMAD2, thereby rendering 
them less responsive to TGF-β1 and reducing the degree of myofibroblast differentiation, a key 
component of the wound healing and scarring process in normal skin. Conditioned media from 
normal fibroblasts could reverse LM affected fibroblast migration and proliferation, suggesting that 
the LM phenotype is driven by an altered secretome. Gene array analysis and RNA-Seq indicated 
upregulation of ADAMTS8 and downregulation of FRAS1 and SOSTDC1. SOSTDC1 knockdown 
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recapitulated the reduced TGF-β1 responsiveness and LM fibroblast migration, whilst overexpression 
of ADAMTS8 induced myofibroblast markers.  
Conclusions: We demonstrate that cell-intrinsic changes in the LM fibroblast secretome lead to 
changes observed in the disease, and that secretome modulation could be a viable therapeutic 
approach in the treatment of LM. 
 
Abbreviations: LM, linear morphoea; TGF-β, transforming growth factor beta; ECM, extracellular 
matrix; ADAMTS8, ADAM metallopeptidase with thrombospondin type 1 motif 8; FRAS1, Fraser 
extracellular matrix complex subunit 1; SOSTDC1, Sclerostin domain containing 1; ALK, activin 
receptor-like kinase; SMAD, mothers against decapentaplegic homolog; MMP, matrix 
metalloproteinase; α-SMA, α-smooth muscle actin; 
 
Keywords: Linear morphoea, fibrosis, migration, proliferation, secreted proteins, TGF-β 
 
INTRODUCTION 
The fibrotic disorder of linear morphoea (LM) represents the most prevalent subtype of localised 
scleroderma (morphoea) in children [1]. Morphoea can be classified according to clinical phenotype 
which include the plaque, generalised, linear, and deep subtypes. LM typically occurs in childhood 
with its prevalence being greater in the young relative to systemic scleroderma (systemic sclerosis) 
[2]. Almost entirely restricted to tissues descended from the mesoderm, it possesses a distinct gene 
signature distinguishable from most systemic scleroderma samples in spite of sharing the principal 
pathology of dysregulated collagen production and degradation [1,3]. Consequently, the disease 
displays thickening and hardening of the skin [2]. In addition to the dermis, the underlying 
subcutaneous tissue, bone and central nervous system are also susceptible [1]. Disease progression 
begins with an inflammatory phase followed by skin hyperaemia, fibrosis, sclerosis and lastly tissue 
atrophy [2]. The poor heritability of the disease, with no identified gene defect, suggests that it is a 
multivariant disorder, with possible risk factors including a family history of autoimmune disease or 
environment events. The disease also shows an approximate 2.5:1 bias toward females [2]. There is 
indication that this disease is a consequence of genetic mosaicism as the lesions correlate with the 
lines of Blaschko [2]. Novel treatment modalities could be informed by the specific gene expression 
differences between the affected and unaffected regions of the skin. 
Fibrosis involves the production of extracellular matrix (ECM) constituents such as collagens during 
the physiological wound healing process as well as in pathologies of excessive or aberrant scarring. 
The fibroblast is responsible for the organisation of the ECM and represents a critical component of 
fibrogenesis. Fibroblasts are activated by mechanical stress to form proto-myofibroblasts, which 
with the addition of the ED-A splice variant of fibronectin and transforming growth factor-β1 (TGF-
β1) differentiate into α-smooth muscle actin (α-SMA) expressing myofibroblasts [4]. The 
myofibroblast is the principal ECM producing cell and their persistence in most fibro-contractive 
diseases highlights their important regulatory role in resolving fibrotic processes [4]. 
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TGF-β1 is a significant facilitator of the fibrosis of many tissues and mediates numerous processes 
that cover differentiation, proliferation, migration, and apoptosis [5]. TGF-β1 is synthesised as a 
precursor which is cleaved intracellularly to produce the latency-associated peptide from the N-
terminus and the TGF-β1 homodimer from the C-terminus [6]. Proteolytically activated TGF-β1 binds 
and induces phosphorylation in its cognate receptor consisting of the TGF-β type I (TβRI) and TGF-β 
type II (TβRII) homodimers [7]. Canonical TGF-β1 signalling is mediated by the specific TβRI activin 
receptor-like kinase (ALK) 5, which upon activation leads to the recruitment and phosphorylation of 
the receptor-regulated mothers against decapentaplegic homolog (SMAD) 2 and 3 [7]. The receptor-
regulated SMADs then complex with the common-mediator SMAD4 and translocate into the nucleus 
to control gene expression [5]. 
The underlying mechanism responsible for the fibrosis of LM is unknown. The aim of this study was 
to improve understanding of the disease by investigating phenotypic differences between fibroblasts 
isolated from LM lesions and normal skin regions. Gene expression analysis was performed to 
identify possible mediators of these distinct disease phenotypes, followed by subsequent over- and 
underexpression of selected genes to identify potential therapeutic targets. We show that LM 
fibroblasts from diseased skin possess a persistent, identifiable cell phenotype in culture exhibiting 
increased cell growth, increased migration, and paradoxically a reduced response to TGF-β1. 
Knockdown and overexpression studies demonstrated that dysregulation of the secretome underlies 
the phenotype of LM fibroblasts. 
 
MATERIALS AND METHODS 
Cell culture 
Human primary dermal fibroblasts were isolated from punch biopsies of affected (A) areas and site-
matched normal (N) regions of consented patients with linear morphoea (Table 1) by 
trypsin/collagenase digestion (Sigma-Aldrich) and were subsequently expanded. Human primary 
dermal fibroblasts and mouse NIH 3T3 fibroblasts were cultured in DMEM (low glucose; Sigma-
Aldrich) supplemented with FBS (10% v/v; ThermoFisher Scientific) and Antibiotic-Antimycotic (1% 
v/v; ThermoFisher Scientific) in a humidified atmosphere of 5% CO2 and 95% air at 37°C, with media 
changes occurring thrice weekly. Cells from passage 3-7 were used in experiments. 
 
Stimuli and inhibitors 
Cells were serum-starved overnight and treated in serum-free culture media. Detection of α-SMA-
expressing fibroblasts was conducted by 48 h serum-reduction in culture media containing FBS (0.1% 
v/v). Cells were treated with the growth factor TGF-β1 (12.5 ng/ml; Sigma-Aldrich) in media 
additionally containing BSA (0.1% w/v; Sigma-Aldrich), the DNA synthesis inhibitor mitomycin C (10 
μg/ml; Sigma-Aldrich) with a 30 min pre-incubation. Control vehicles were culture media plus BSA 
(0.1% w/v) in place of TGF-β1, and dimethyl sulphoxide (DMSO; 0.1% v/v; Sigma-Aldrich) in place of 
the inhibitors. Conditioned media was generated by serum-starving cells for 24 h followed by 2 
rinses in PBS (MP Biomedicals) and incubating cells with serum-free media for 24 h; this was mixed 
1:1 with fresh serum-free DMEM before application to replenish depleted nutrients. 
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Transfection and transduction of fibroblasts 
Mouse NIH 3T3 fibroblasts were stably transfected with Lipofectamine 2000 (Invitrogen) with mouse 
Sostdc1 (NM_025312) SureSilencing shRNA Plasmids (Qiagen), or scrambled sequence negative 
control plasmids (Qiagen) according to manufacturer’s instructions. Cells were selected in fresh 
complete media containing G 418 (400 μg/ml; Sigma-Aldrich) and were maintained in G 418 (200 
μg/ml). Sostdc1 protein levels in conditioned media were assessed following PNGase F (New England 
Biolabs) treatment for 1 h to remove glycosylations. 
Linear morphoea normal primary dermal fibroblasts were stably transduced with: ADAMTS8 
(NM_007037) Human LentiORF Particles (pLenti-C-mGFP-P2A-Puro; OriGene) for overexpression, or 
LentiORF Control Particles (pLenti-C-mGFP-P2A-Puro; OriGene) as an empty vector control. Cells at 
~50% confluency were incubated overnight in complete media with polybrene (8 μg/ml; Sigma-
Aldrich) at an MOI of 6. Subsequently, the lentivirus-containing media was replaced with fresh 
complete media for 24 h. Cells were then selected in fresh complete media plus puromycin (2 μg/ml; 
Sigma-Aldrich) according to a puromycin titration (data not shown) to select for successfully 
transduced cells. After ~10 days, with selection media being replaced routinely every 3-4 days, 
puromycin-resistant colonies were expanded and used in experimentation. 
 
BrdU incorporation proliferation assay 
Cells were seeded in triplicate into a 96 well microplate at a density of 1 × 103 cells/cm2, cultured 
overnight and BrdU incorporation with visualisation by peroxidase was assayed according to 
manufacturer’s instructions (Millipore). Absorbance (450 nm) was detected with the Multiskan EX 
spectrophotometer (Thermo Scientific). 
 
Scratch motility assay 
Cells were seeded in triplicate into 6 well plates at a density of 5 × 104 cells/cm2 and cultured 
overnight. Confluent cells were pre-incubated for 30 min with mitomycin C (10 μg/ml) to inhibit 
proliferation, scratched with a 20 μl pipette tip, rinsed twice in serum-free DMEM to remove cell 
debris, and then incubated in DMEM containing mitomycin C (10 μg/ml) plus additional treatments. 
Images were taken in triplicate for each condition with the Olympus IX71 inverted microscope and 
HCImage Live (v4.3) capture software at 0 h to acquire baseline images, and at the experiment end-
point of 24 h. Image analysis was conducted using the Fiji distribution of ImageJ (v1.51n). The 
denuded area was measured using the ‘Polygon Selection’ tool. End-point data was normalised to 
the denuded area at 0 h. 
 
Adhesion assay 
Cells were seeded into a 96 well microplate at a density of 1 × 104 cells/cm2, cultured overnight, and 
treatments applied. At the experiment end-point, non-adherent cells were removed by rinsing in PBS 
and the microplate was then frozen at −70°C for at least 24 h to allow for efficient cell lysis. The 
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microplate was thawed and incubated for 5 min, protected from light, with a solution of the nucleic 
acid fluorescent dye CyQUANT GR (1×, excitation: 485 nm, emission 520 nm; ThermoFisher 
Scientific) and Cell Lysis Buffer (1×; ThermoFisher Scientific) according to the manufacturer’s 
instructions. The sample fluorescence was then measured with the FLUOstar OPTIMA fluorescence 
plate reader (BMG Labtech). 
 
Collagen gel contraction assay 
Into 6 well plates 1 × 105 cells/well were mixed with a solution of Bovine Collagen I (4 mg/ml; 
Invitrogen) and Hank’s Balanced Salt Solution (1×, pH 7.2; Sigma-Aldrich), seeded and allowed to set 
at 37°C in a stainless steel washer (135 mm), which was subsequently removed. Baseline 0 h images 
and day 8 end-point images were acquired using the Leica DFC320 microscope (Leica Microsystems). 
Gel contraction was measured as gel area at day 8 normalised to the initial gel area of 0 h images 
using the Fiji distribution of ImageJ. 
 
TGF-β1 ELISA 
Secreted TGF-β1 in 24 h conditioned media was determined using the Human/Mouse TGF beta1 
ELISA Ready-SET-Go! (2nd Generation; eBioscience) according to manufacturer’s instructions. 
Absorbance (450 nm) was detected with the Multiskan EX spectrophotometer. 
 
Immunofluorescence 
Paraffin-embedded tissue sections (5 μm) were prepared with standard protocols. To study 
immunofluorescence in vitro, cells on coverslips were fixed and permeabilised for 10 min in a warm 
solution of PFA (4% v/v) and Triton X-100 (0.1% v/v; Sigma-Aldrich), followed by a 5 min wash in PBS. 
Tissue sections and in vitro samples were blocked for 30 min or 1 h, respectively, in Fish Skin Gelatin 
(0.8 % v/v; Sigma-Aldrich) plus Triton X-100 (0.2 % v/v). Primary antibodies (SOSTDC1, 1:500, Abcam; 
ACTA2, 1:500, Dako; p-SMAD2, 1:250, Cell Signaling Technology; p-SMAD2,3, 1:250, Cell Signaling 
Technology; ADAMTS8 2H5, 1:100, Novus Biologicals; FRAS1 H-300, 1:200, Santa Cruz Biotechnology) 
diluted in blocking buffer were incubated at 4°C overnight. Sections and cells were washed in PBS-
Tween 20 (PBS-T, 0.1% v/v; Sigma-Aldrich) and then incubated at room temperature for up to 1 h 
with Alexa Fluor-conjugated secondary antibodies (1:500; Invitrogen) diluted in blocking buffer. 
Sections and cells were mounted in ProLong Gold Antifade Mountant with DAPI (Invitrogen). Images 
were acquired with Micro-Manager (v1.4.21) software and analysis was performed with the Fiji 
distribution of ImageJ. Picrosirius red histology was imaged using an epifluoresence microscope with 
side illumination. 
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Western blotting 
Protein lysates were harvested on ice by scraping and vortexing with lysis buffer [Tris-HCl (20 mM), 
pH 7.5, NaCl (150 mM), EDTA (1 mM), Triton X-100 (1% v/v), sodium deoxycholate (0.5% w/v), SDS 
(0.1% w/v), protease inhibitor cocktail (1×; Roche), phosphatase inhibitor cocktail (2×; Roche)]. 
Protein concentration was quantified with the Bradford Protein Assay (Bio-Rad). Equal amounts 
were electrophoresed in Mini-PROTEAN TGX Precast Protein Gels (4-20%; Bio-Rad) in Tris-Glycine-
SDS buffer [1×, Tris base (0.25 M), glycine (1.92 M), SDS (1% w/v); Scientific Laboratory Supplies]. 
Proteins were transferred onto Amersham Protran Nitrocellulose Blotting Membranes (0.45 μm; GE 
Life Sciences) with Pierce Western Blot Transfer Buffer (ThermoFisher Scientific). Membranes were 
blocked for 30 min in dried skimmed milk (5% w/v; Marvel) in PBS-T and incubated at 4°C overnight 
with primary antibodies (p-SMAD2, 1:250, Abcam; SMAD2, 1:500, Cell Signaling Technology; p-
SMAD3, 1:250, Cell Signaling Technology; SMAD3, 1:250, Cell Signaling Technology; MMP-2, 1:250; 
Alpha Smooth Muscle Actin, 1:250, Abcam; ADAMTS8 2H5, 1:500, Novus Biologicals; FRAS1 H-300, 
1:200, Santa Cruz Biotechnology; GAPDH, 1:2000, Merck-Millipore). Subsequently, membranes were 
subjected to 5 min washes in PBS-T and then incubated with HRP-conjugated secondary antibodies 
(1:3000; Dako). Membranes were visualised with the Amersham ECL Prime detection kit (GE Life 
Sciences) and Hyperfilm ECL (GE Life Sciences). Densitometry was performed with the Fiji 
distribution of ImageJ. 
 
Gelatin zymography 
Equal volumes of 24 h conditioned media aspirated from 1 × 106 cells for each condition were 
separated by non-denaturing electrophoresis in a gelatin (0.5% w/v) acrylamide-bis-acrylamide gel 
(7.5% w/v), and then incubated for 24 h at 35°C in enzymatic reaction buffer [Tris-HCl (0.05 M), pH 
7.4, NaCl (20 mM), CaCl2 (5 mM), NaN3 (0.02% w/v)] to allow digestion of gelatin. The gel was 
stained with Coomassie Brilliant Blue R-250 Dye (ThermoFisher Scientific) at room temperature for 
~10 min to detect undigested regions and was subsequently destained with a solution of methanol 
(30% v/v) and acetic acid (10% v/v). MMP bands were discerned by protein size with reference to a 
protein ladder. Conditioned media run in gels lacking gelatin and stained with Coomassie Brilliant 
Blue R-250 Dye was used as a loading control. 
 
Microarray analysis and RNA sequencing 
Total RNA was extracted from low passage number cells and DNase treated with the RNeasy kit 
according to manufacturer’s instructions (Qiagen). RNA quality was assessed with a Nanodrop 2000c 
spectrophotometer (Thermo Scientific) and an Agilent Bioanalyser 2100 (Agilent Technologies). Total 
RNA (~2 μg) from each sample was used to generate double-stranded cDNA using a T7-oligo (dT) 
primer. Biotinylated cRNA, produced by in vitro transcription, was fragmented and hybridised to an 
Affymetrix Human Genome U133 Plus 2.0 microarray (48,000 probesets; ThermoFisher Scientific). 
The arrays were processed with a GeneChip Fluidics Station 450 (ThermoFisher Scientific) and 
scanned on an Affymetrix GeneChip Scanner (ThermoFisher Scientific), according to standard 
protocols. Expression signals were normalised to remove background noise and non-biological 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
variations amongst arrays. Background noise was removed from the PM probe intensities using the 
“RMA” method. Primary data was calculated using both Microarray Analysis Suite (v5.0; Affymetrix) 
including mismatch probeset controls and GC-RM (quantile normalised). 
RNA-Seq was performed by UCL Genomics with libraries being synthesised from total RNA (2 μg) 
with an RNA integrity value of > 8 in all cases; libraries were sequenced with a 36 bp paired end 
read. The generated FastQ files were mapped against the Homo sapiens reference sequence 
GRCh37/hg19 using Bowtie, TopHat and SAMtools; duplicate reads were removed with SAMtools 
and read counts per gene were generated using HTSeq-count. EdgeR (Bioconductor) was used to 
normalise gene expression and generate lists of differentially expressed genes (DEGs). DEGs altered 
at least 2-fold in expression with P value < 0.05 in ≥ 4 of 5 sample pairs. This trimmed data set was 
then analysed by DAVID for gene ontology (GO) term enrichment with Bonferroni correction for 
multiple testing. 
 
RESULTS 
LM fibroblasts are hyperproliferative, hypermigratory, with altered collagen processing 
Tissue harvested from LM patients of affected lesions and site-matched normal skin was stained 
with haemotoxylin and eosin. There were clumps of vimentin positive fibroblasts in the reticular 
dermis distal from the epidermis in affected dermis, but overall numbers of fibroblasts were 
unchanged.  Collagen arrangement was altered in the dermis according to picrosirius red staining  
(Figure 1A). Differences between LM fibroblasts from normal and affected areas were investigated 
using primary human dermal fibroblasts isolated and cultured in vitro (Table 1). Given the relative 
increased presence of fibroblasts in affected regions, proliferation was studied by performing cell 
counts on fibroblasts initially seeded at equal densities and cultured for 3, 6, 8 and 10 days. At day 
10, affected fibroblasts exhibited a greater cell number relative to normal fibroblasts cultured for 10 
days (Figure 1B). BrdU incorporation into proliferating cells was increased relative to normal 
fibroblasts (Figure 1C).  
Fibroblast motility was investigated with a scratch assay. The denuded area at 24 h post-scratch with 
affected fibroblasts was reduced compared to normal fibroblasts indicating increased relative 
migration (Figure 1D). Activated fibroblasts involved in scar formation during wound healing and 
fibrotic pathologies exhibit an increase in the capacity to contract collagen gels [8,9]. However, 
affected fibroblasts demonstrated a diminished capacity to contract collagen gels relative to normal 
fibroblasts (Figure 1E). TGF-β1 is integral to the development of differentiated myofibroblasts and, 
consequently, is critically implicated in fibrosis [10,11]. Conditioned media supernatant harvested 
after 24 h incubation with normal and affected LM fibroblasts did not contain differing levels of 
secreted TGF-β1 as detected by ELISA (Figure 1F). 
Matrix metalloproteinases (MMPs) such as MMP-2 are increased in expression and activity in 
activated fibroblasts [12]. Western blot analysis of conditioned media from affected fibroblasts 
displayed modestly (1.3X) increased levels of MMP-2 protein relative to normal fibroblasts (Figure 
1G). Additionally, affected fibroblasts demonstrated significantly greater MMP-2 activity relative to 
normal fibroblasts when conditioned media was subjected to gelatin zymography (Figure 1G and H). 
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Taken together, LM fibroblasts are hyperproliferative, hypermigratory and have higher levels of 
collagen processing than fibroblasts at site-matched normal regions of the same individual. 
 
Altered response to TGF-β1 on the proliferation and adhesion of LM fibroblasts 
TGF-β1 mediates various cellular processes of fibroblasts [13]. To assess the potential modulation of 
LM fibroblast phenotype, cells were treated with TGF-β1 (12.5 ng/ml) for 24 h and proliferation was 
assayed by BrdU incorporation. Although BrdU levels in affected fibroblasts were elevated in 
comparison to normal fibroblasts, this relative increase was attenuated by TGF-β1 treatment (Figure 
2A). 
To explore the effect of secreted factors on LM fibroblast motility, cells were incubated with culture 
media conditioned for 24 h with the opposite fibroblast type (i.e. normal on affected cells or 
affected on normal cells) following a scratch in the presence of mitomycin C (10 μg/ml). The 
increased motility of affected fibroblasts relative to normal fibroblasts was reduced when the 
culture media was replaced with that conditioned by normal fibroblasts (Figure 2B). Conditioned 
medium from affected fibroblasts had no effect on motility of normal fibroblasts (Figure 2B). The 
influence of a fibrotic environment on the adhesion ability of LM fibroblasts was investigated by 
incubating cells for 24 h with either TGF-β1 (12.5 ng/ml) or media conditioned for 24 h with the 
opposite fibroblast type. Non-adherent cells were removed by rinsing in PBS and remaining cells 
were assessed by incubation with the nucleic acid fluorescent dye CyQUANT GR. The adhesion of 
affected fibroblasts was significantly lower than of normal fibroblasts (Figure 2C). TGF-β1 treatment 
decreased normal fibroblast adhesion without altering the reduced adhesion of affected fibroblasts 
further (Figure 2C). Conditioned media incubation greatly decreased normal fibroblast adhesion and 
consequently demolished the difference relative to affected fibroblasts (Figure 2C). Therefore, 
proliferation and adhesion along with the resulting response to TGF-β1 treatment are altered in 
affected fibroblasts. 
The differentiated myofibroblast, whose persistence is central to the fibrotic lesions of many 
disorders, is typified by the expression of α-SMA [10]. LM lesion-associated fibroblasts demonstrated 
increased α-SMA relative to normal fibroblasts (Figure 2E). TGF-β1 (12.5 ng/ml) treatment for 24 h 
increased α-SMA protein in normal fibroblasts, whereas this was limited in affected fibroblasts 
(Figure 2E). Affected fibroblasts also displayed less α-SMA immunofluorescence staining 24 h post-
scratch wounding relative to normal fibroblasts (Figure 2F). 
TGF-β1 signalling can occur through distinct pathways that involve SMAD2/3 [14]. Affected LM 
fibroblasts displayed a reduced level of SMAD2 immunofluorescence staining 30 min post-scratch 
wounding relative to normal cells (Figure 2D). To better understand this differential response of LM 
fibroblasts following TGF-β1 stimulation, downstream SMAD signalling was investigated. In 
unstimulated conditions affected fibroblasts possessed an elevated level of p-SMAD2 protein 
detected by western blotting relative to normal cells, whereas p-SMAD3 protein levels did not differ 
(Figure 2G). The application of TGF-β1 (12.5 ng/ml) for 30 and 60 min did not significantly increase p-
SMAD3 levels relative to untreated normal cells (Figure 2G). Increased levels of p-SMAD2 in affected 
fibroblasts were not elevated further with TGF-β1 stimulation (Figure 2G). 
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LM lesions lack SMAD2 phosphorylation compared to scleroderma 
Following the discovery of variance in p-SMAD2 and 3 levels between LM fibroblasts harvested from 
normal and affected regions, differences in LM and scleroderma skin tissue was additionally 
investigated. Immunohistochemistry revealed widespread nuclear p-SMAD3 staining in the dermis of 
LM and scleroderma skin, both in the dermis and epidermis (Figure 3A). However, the presence of 
increased nuclear p-SMAD2 was significantly more frequent in dermis of scleroderma skin compared 
to LM or normal skin (Figure 3B). Therefore, the reduced nuclear p-SMAD2 expression seen in LM 
may be diagnostic of the disease. 
 
Gene expression analysis indicates consistent changes in the LM fibroblast secretome 
To characterise the differences inherent in LM fibroblasts of affected lesions and normal skin, gene 
expression analysis was performed. Microarray gene expression analysis (normal 1, 2, 3, and 
affected 1, 2, 3) was combined with RNA-Seq data (normal 4, 5, and affected 4, 5) which identified 
39 significantly differentially expressed genes by at least 2-fold that were common to ≥ 4 of the 5 
normal/affected pairs (Figure 4A). Organ development, morphogenesis, tissue development, and 
extracellular proteins were the only over-represented gene ontology (GO) groups determined by 
DAVID GO term enrichment (Figure 4B). Of the 39 differentially expressed genes, 9 were secreted 
proteins (Figure 4C). As the secretome of normal cells could rescue the disease-associated 
phenotype of LM lesion affected fibroblasts, the subset of differentially expressed genes encoding 
secreted factors was further examined for fibrosis-centric proteins such as those known to modulate 
TGF-β1 signalling or the extracellular matrix (Figure 4C). From this subset Sclerostin domain 
containing 1 (SOSTDC1), ADAM metallopeptidase with thrombospondin type 1 motif 8 (ADAMTS8), 
and Fraser extracellular matrix complex subunit 1 (FRAS1) were chosen for further study (Table 2, 
Figure 4D). 
 
Sostdc1 knockdown increases migration and reduces proliferation and TGF β1 response 
SOSTDC1 is a secreted antagonist of TGF-β superfamily members and a modulator of Wnt signalling, 
both pathways that promote fibrosis [15–17]. Immunofluorescence staining of SOSTDC1 in LM skin 
tissue revealed a reduced signal in fibroblasts of affected regions relative to normal fibroblasts 
(Figure 5A). Additionally, SOSTDC1 protein expression was reduced in both the lysate and 
conditioned media supernatant of affected fibroblasts in vitro relative to normal cells (Figure 5B). 
SOSTDC1 was secreted in glycosylated form, and PNGaseF treatment was necessary to resolve 
secreted SOSTDC1 expression in conditioned medium.  
To study the effect of SOSTDC1 downregulation in LM fibroblasts, mouse NIH 3T3 fibroblasts were 
transfected with either a scrambled sequence shRNA control or Sostdc1 shRNA. Conditioned media 
supernatant harvested from Sostdc1 shRNA transfected NIH 3T3 cells possessed reduced levels of 
Sostdc1 protein relative to scrambled shRNA transfected cells (Figure 5C). Sostdc1 shRNA 
transfected fibroblasts exhibited a relative reduction in cell number after 10 days of in vitro culture 
compared to scrambled shRNA transfected cells (Figure 5D). Fibroblasts transfected with Sostdc1 
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shRNA also demonstrated an increase in migration relative to the scrambled shRNA control (Figure 
5E). MMP2 levels and activity were unchanged in Sostdc1 knockdown fibroblasts (Figure 5F). 
The influence of Sostdc1 knockdown on TGF-β1 downstream signalling was investigated by treating 
scrambled or Sostdc1 shRNA transfected NIH 3T3 fibroblasts with or without TGF-β1 (12.5 ng/ml) for 
3 or 6 h. Scrambled shRNA expressing controls exhibited increased p-SMAD2 protein in response to 
TGF-β1, whereas in Sostdc1 shRNA transfected cells following TGF-β1 stimulation SMAD2 
phosphorylation was limited (Figure 5G). 
To investigate the result of Sostdc1 downregulation on fibroblast phenotype, NIH 3T3 cells were 
transfected with either scrambled or Sostdc1 shRNA, and treated with or without TGF-β1 (12.5 
ng/ml) with an increasing duration of serum starvation (0, 2 or 24 h). In normal culture conditions 
Sostdc1 shRNA expressing fibroblasts possessed elevated levels of α-SMA relative to the respective 
scrambled shRNA control (Figure 5H). TGF-β1 treatment of scrambled shRNA fibroblasts increased α-
SMA levels relative to untreated scrambled shRNA cells, whereas TGF-β1 treatment of Sostdc1 
shRNA fibroblasts reduced α-SMA relative to untreated Sostdc1 shRNA cells (Figure 5H). 
 
FRAS1 protein expression is lost in LM fibroblasts and in the dermis of LM affected skin 
FRAS1 is an ECM protein that mediates epidermal-dermal adhesion and is capable of activating TGF-
β family members [18–20]. FRAS1 protein was decreased in LM affected fibroblasts relative to 
normal cells, thereby reflecting the gene expression analysis results (Figure 6A). 
Immunofluorescence staining of FRAS1 in LM skin tissue ex vivo was reduced in dermal fibroblasts 
associated with LM lesions compared to normal sites. Furthermore, widespread staining of FRAS1 
was seen in the dermis not localised to fibroblasts, whilst epidermal FRAS1 levels did not significantly 
change (Figure 6B). This suggests that secretion of FRAS1 into the dermis is significantly decreased in 
LM. 
 
Overexpression of ADAMTS8 induces smooth muscle actin expression in normal fibroblasts 
ADAMTS8 is a member of the ADAMTS family of secreted metalloproteases which are implicated in a 
diverse array of functions including migration, adhesion, proliferation and growth factor signalling 
[21,22]. ADAMTS8 protein levels were increased in affected fibroblasts associated with LM lesions 
relative to fibroblasts harvested from normal sites (Figure 6C). Similarly, ADAMTS8 
immunofluorescence staining was increased in LM affected fibroblasts relative to normal fibroblasts 
(Figure 6D). 
To study the effect of ADAMTS8 expression on fibroblast phenotype, LM fibroblasts from normal 
regions were transduced with either an empty vector control or an ADAMTS8 overexpression vector. 
Fibroblasts overexpressing ADAMTS8 demonstrated an increase in ADAMTS8 protein relative to the 
empty vector control (Figure 6E). Protein levels of α-SMA were elevated following ADAMTS8 
overexpression relative to the empty vector control and thereby emulated the increase observed in 
affected cells relative to normal fibroblasts (Figure 6E). 
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DISCUSSION 
LM is a mosaic disease where cells present in normal skin and lesions possess a heterogeneous 
phenotype which is responsible for their separate histology and, consequently, pathology [2]. We 
show that LM affected fibroblasts possessed a distinct cell-intrinsic phenotype which is responsible 
for many aspects of disease pathology: increased proliferation, migration, MMP-2 activity, and 
decreased adhesion. These processes are integral to normal fibroblast function during wound 
healing and scar formation [23,24]; some of which are additionally involved in scleroderma [25,26]. 
Constitutive SMAD2 phosphorylation and subsequent insensitivity to TGF-β1 also contributed to the 
LM phenotype. Conditioned media swap experiments confirmed that the disease phenotype is 
driven by secreted proteins. Furthermore, a discrete set of differentially expressed genes, including 
downregulated SOSTDC1 and upregulated ADAMTS8, promoted different facets of the LM 
phenotype. It is important to consider when interpreting these experiments that there may be 
systemic effects caused by methotrexate treatment, although these should be controlled for by site 
matching in the same patient, or that there may be underlying genetics that predispose to LM. Both 
could change the biology of the fibroblasts even in the unaffected sites 
The finding herein of unaltered levels of TGF-β1 secretion between normal and affected fibroblasts 
agrees with studies investigating TGF-β1 in skin and blood of various forms of scleroderma [13,27]. 
Although no difference in TGF-β1 secretion existed between normal and affected fibroblasts, there 
was instead a distinct response to TGF-β1 in LM fibroblasts. The reduction in affected fibroblast 
proliferation with TGF-β1 stimulation indicates a transition to the myofibroblast phenotype, where 
differentiation leads to a contractile phenotype whilst proliferation ceases [4]. This altered TGF-β1 
responsiveness could be attributed to LM fibroblasts being skewed towards a myofibroblast 
phenotype, consistent with the increased α-SMA expression in resting affected fibroblasts, however 
there may be a stall in the differentiation to a full myofibroblast phenotype as contraction of 
collagen gels was impaired. It is possible that incomplete myofibroblast differentiation is 
contributing to the fibrotic phenotype in LM 
Canonical TGF-β1 signalling occurs through the phosphorylation and activation of SMAD2 and 
SMAD3 [5]. LM tissue displayed a distinct profile of SMAD phosphorylation exhibiting lower p-
SMAD2 relative to scleroderma, whereas p-SMAD3 was similar between them. Localised 
scleroderma fibroblasts exhibit constitutive DNA-SMAD3 binding which was reflected herein [28]. In 
LM affected fibroblasts it was only SMAD2 that portrayed elevated phosphorylation in the resting 
state. The implication of this constitutive activation is seen in the elevated α-SMA and consequent 
myofibroblast phenotype. In human lung fibroblasts, unlike SMAD3, SMAD2 overexpression results 
in a TGF-β1-independent alteration of phenotype with an increase in α-SMA [29]. This reinforces 
SMAD2, not SMAD3 as a crucial mediator in the control of LM fibroblast phenotype. When affected 
fibroblasts were stimulated into action by either scratch wounding or TGF-β1 treatment, levels of 
SMAD2 were lower relative to normal cells and this was also reflected in the reduced α-SMA. This 
suggests a defect in the ability of affected fibroblasts to respond to such stimuli. A further reason 
aside from a general dysregulation of SMAD signalling may be that myofibroblasts in dense cultures, 
such as those arising from the increased proliferation witnessed in affected LM fibroblasts, decrease 
α-SMA expression and de-differentiate into α-SMA-negative fibroblasts due to contact-induced 
desensitisation to TGF-β1 [30]. 
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SOSTDC1 is an inhibitor of bone morphogenetic proteins (BMPs), which belong to the TGF-β 
superfamily, that prevents cognate receptor association by directly binding to BMPs [16,17]. 
SOSTDC1 is further indirectly related with TGF-β signalling through its interaction with the Wnt 
pathway which is activated in many fibrotic diseases [15,31,32]. Therefore, the decreased SOSTDC1 
expression and secretion in LM represents a mechanism for the fibrosis, as inhibition of Wnt and 
SMAD signalling is lost. Sostdc1 knockdown caused a relative decrease in proliferation contrary to 
the elevated proliferation of LM affected fibroblasts. It is possible that the resulting disinhibition of 
TGF-β signalling promotes the fully differentiated, pro-contraction and anti-proliferation 
myofibroblast phenotype [4]. However, the Sostdc1 shRNA was sufficient to induce the migratory 
phenotype of affected LM fibroblasts. This is consistent with the concept that LM fibroblasts are 
migratory, activated myofibroblast-like cells. 
The diminished p-SMAD2 response and limited α-SMA induction with TGF-β1 treatment of Sostdc1 
transfected fibroblasts mirrored the lack of responsiveness seen in affected LM fibroblasts. 
Therefore, reduced SOSTDC1 is likely a driver of TGF-β1 insensitivity in LM fibroblasts. As SOSTDC1 
can affect both the TGF-β and Wnt signalling pathways, it is attractive to suggest that loss of 
SOSTDC1 or related genes can perturb myofibroblast differentiation to induce a pro-fibrotic dermal 
environment. Sostdc1 shRNA transfection reproduced the increase in MMP-2 activity and 
consequent fibroblast migration. However, transfection alone was insufficient to replicate the 
increase in MMP-2 protein secretion. Since MMP-2 can activate TGF-β1, this suggests that affected 
fibroblasts could experience a greater TGF-β1 response and SMAD2 phosphorylation without a 
change in TGF-β1 levels [12]. 
LM tissue and affected fibroblasts possessed a relative decrease in FRAS1 gene expression that was 
replicated at the protein level both in vitro and in LM skin tissue ex vivo. Mutations in FRAS1 are 
responsible for Fraser syndrome which is a severe multisystem condition that occurs during 
development in utero where 45% of individuals are stillborn or die within a year, whilst those that 
survive are developmentally delayed [18,20]. Mutations in the Fras1 gene produce epidermal-
dermal adhesion defects which manifests as large blisters [19]. This is caused by a defective ECM 
arising from a mid-gestational developmental defect potentially accompanied by a dysregulation of 
TGF-β signalling [18]. This is consistent with the significantly lower adhesion of affected LM 
fibroblasts. Moreover, affected fibroblast conditioned media decreased the adhesion of normal 
fibroblasts implicating a secreted factor, potentially FRAS1, in this facet of the LM phenotype. 
The diverse ADAMTS metalloprotease family are structurally similar to the MMP and ADAM 
proteases; accordingly, they possess similar and overlapping functionality [22,33]. The increased 
relative expression of ADAMTS8 in affected fibroblasts was reproduced at the protein level. Elevated 
levels of ADAMTS8 in affected fibroblasts can help explain their enhanced motility as the greater 
ECM remodelling leads to a less dense matrix which would otherwise impede migration [11]. 
Upregulation of ADAMTS4 and ADAMTS5, which belong to the proteoglycanase sub-group alongside 
ADAMTS8, are involved in the over-degradation of cartilage ECM in osteoarthritis [11]. An analogous 
process could occur in LM, with ADAMTS8 upregulation being a factor in the observed tissue 
atrophy. In nasopharyngeal carcinoma cell lines expressing ADAMTS8, apoptosis was induced and 
this could potentially act synergistically with the above mechanism to contribute to the atrophy [22]. 
ADAMTSs are secreted and are capable of cleaving and activating growth factors that are embedded 
in the ECM such as TGF-β1; a process shared by MMPs, including MMP-2, which are also secreted 
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[34,35]. In normal fibroblasts overexpressing ADAMTS8, α-SMA protein was induced which is 
consistent with an effect on TGF-β1 signalling. 
Overall, these data highlight the importance of the secretome in LM and normal secretome 
replacement or addition of normal cells in affected areas may be a relatively simple and viable 
treatment. An improved understanding of the function of the altered LM secretome will lead to 
viable targeted therapies capable of modulating TGF-β1 signalling with more control so as to prevent 
fibrosis and atrophy. 
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Figure 1. LM affected fibroblasts are hyperproliferative, hypermigratory, with elevated 
collagen processing. A. Histology of LM affected lesion and site-matched normal skin stained 
with haemotoxylin and eosin; deep dermis denotes the reticular dermis distal from the epidermis. 
Bar 50μm. B. Growth curve obtained from cell counts of primary human dermal fibroblasts isolated 
from LM affected lesions and site-matched normal skin cultured in vitro for 10 days. C. BrdU 
incorporation measured by absorbance (450 nm) in confluent normal and affected fibroblasts. D. 
Representative cell motility (scratch) assay image of normal and affected fibroblasts where the 
monolayer was scratched following a 30 min pre-incubation with mitomycin C (10 μg/ml) to inhibit 
proliferation, and the denuded area measured after 24 h in the continued presence of mitomycin C. 
Bar 50μm. Graph (right) shows denuded area normalised to denuded area at 0 h. E. Collagen gel 
contraction assay performed on normal and affected LM fibroblasts for 8 days. Graph (right) shows 
gel area normalised to gel area at day 0. F. TGF-β1 ELISA of conditioned media supernatant from 
overnight serum-starved normal and affected fibroblasts harvested after 24 h incubation. G. 
Representative western blot analysis (top) and zymography (bottom) of MMP-2 protein in lysates 
and conditioned media from normal and affected LM fibroblasts respectively. H. Graph of 
normalised MMP-2 activity in normal and affected conditioned media as measured by zymography  . 
*** P < 0.001, ** P < 0.01, * P < 0.05, Paired T-test. All data expressed as mean ± S.E.M. n=2 
different normal and affected pairs. Representative data is shown. 
 
Figure 2. LM affected fibroblasts are insensitive to exogenous TGF-β1 and scratch 
wounding. A. BrdU incorporation in confluent normal and affected fibroblasts treated with TGF-β1 
(12.5 ng/ml) or the control vehicle DMSO (0.1% v/v) for 24 h. B. Cell motility (scratch) assay of 
normal and affected fibroblasts after 24 h incubation with or without media conditioned for 24 h 
from the opposite fibroblast type in the presence of mitomycin C (10 μg/ml) with a 30 min pre-
incubation. Graph (right) shows mean denuded area normalised to denuded area at 0 h. C. Cell 
adhesion assay of normal and affected fibroblasts incubated for 24 h with media alone, or TGF-β1 
(12.5 ng/ml), or media conditioned for 24 h with the opposite fibroblast type. Nucleic acid 
fluorescence is proportional to adherent cell number. * P < 0.05 vs normal, *** P < 0.001 vs normal, 
†† P < 0.01 vs normal + TGF-β1, paired T-test. D. Representative immunofluorescence staining of 
SMAD2 in normal and affected fibroblasts in vitro 30 min post-scratch. E. Representative western 
blot of α-SMA (ACTA2) protein in normal and affected fibroblasts treated with or without TGF-β1 
(12.5 ng/ml) for 24 h. GAPDH was used as a loading control. F. Representative immunofluorescence 
staining of α-SMA (ASMA) protein in normal and affected fibroblasts in vitro 24 h post-scratch. Bar 
50 μm. G. Representative western blot analysis of p-SMAD2 and p-SMAD3 protein in normal and 
affected fibroblasts treated with TGF-β1 (12.5 ng/ml) for 30 min and 60 min. GAPDH was used as a 
loading control. Graphs (bottom) show normalised densitometry values. * P < 0.05 vs normal (0 
min), † P < 0.05 vs affected (0 min), Paired T-test. All data expressed as mean ± S.E.M. n=2 different 
normal and affected pairs. Representative data is shown. 
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Figure 3. Lack of SMAD2 phosphorylation is diagnostic of LM. A. Representative p and p-
SMAD2 immunofluorescence and p-SMAD3 immunohistochemistry from the dermis of normal skin 
(n = 5), linear morphoea (n = 9), and scleroderma (n = 3). Bar 50 µm. B. Scoring of presence (black) or 
absence (white) of nuclear p-SMAD2 and p-SMAD3 in the dermis of normal skin (Nor), linear 
morphoea (Mor) or scleroderma (Scl). * P < 0.05, Fisher’s exact test. 
 
Figure 4. Gene expression analysis of differentially expressed genes in LM. A. Heat map 
and cluster analysis of significantly (> 2 fold, P < 0.05 in ≥ 4 of 5 sample pairs) differentially expressed 
genes (DEG) of matched normal and affected pairs (n = 5; 3 by microarray, 2 by RNAseq). Yellow 
denotes upregulation, blue downregulation. B. Gene ontology (GO) groups over-represented from 
the differentially expressed genes in LM fibroblasts. Results displayed as 1/P value with Bonferroni 
correction for multiple testing. C. Mean fold change of differentially expressed secreted factors in 
LM fibroblasts. D. Pairwise investigation (N1 vs A1, N2 vs A2, etc.) of ADAMTS8, FRAS1 and SOSTDC1 
expression in 5 pairs of samples. P values are shown for Wilcoxon rank sum test. 
 
Figure 5. Sostdc1 knockdown increases migration, reduces proliferation, and causes 
TGF-β1 insensitivity. A. Representative immunofluorescence staining of SOSTDC1 in normal and 
affected LM skin tissue ex vivo. B. Representative western blot analysis of SOSTDC1 protein in cell 
lysate and conditioned media supernatant from normal and affected LM fibroblasts cultured in vitro. 
GAPDH was used as a loading control. C. Representative western blot analysis of Sostdc1 protein in 
conditioned media supernatant from mouse NIH 3T3 fibroblasts transfected with either a scrambled 
sequence shRNA control or Sostdc1 shRNA, and processed with or without PNGase. Equal loading of 
conditioned medium was confirmed with Ponceau red (B, C). D. Growth curve of scrambled shRNA 
or Sostdc1 shRNA transfected NIH 3T3 fibroblasts cultured for 10 days. * P < 0.05 vs scrambled 
shRNA (day 10). E. Cell motility (scratch) assay of scrambled shRNA or Sostdc1 shRNA transfected 
NIH 3T3 fibroblasts after 24 h in the presence of mitomycin C (10 μg/ml) with a 30 min pre-
incubation. Graph (bottom) shows denuded area normalised to denuded area at 0 h. * P < 0.05 vs 
scrambled shRNA. F. NIH 3T3 fibroblasts transfected with either scrambled shRNA or Sostdc1 shRNA, 
in which lysates were subjected to gelatin zymography (top) or western blot analysis (bottom) of 
MMP-2. G. Representative western blot analysis of p-SMAD2 and SMAD2 protein in NIH 3T3 
fibroblasts transfected with either scrambled shRNA or Sostdc1 shRNA, with or without TGF-β1 
treatment (12.5 ng/ml) for 3 or 6 h. GAPDH was used as a loading control. H. Representative western 
blot analysis of α-SMA (ACTA2) protein in NIH 3T3 fibroblasts transfected with either scrambled 
shRNA or Sostdc1 shRNA, and treated with or without TGF-β1 (12.5 ng/ml) with increasing duration 
of serum starvation (0, 2 or 24 h). GAPDH was used as a loading control. All data expressed as mean 
± S.E.M. unpaired T-test, n=3 biological replicates. Representative data is shown 
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Figure 6. FRAS1 dermal expression is reduced in LM skin; ADAMTS8 overexpression 
induces smooth muscle actin expression. A. Representative western blot analysis of FRAS1 
protein levels in normal and LM affected fibroblasts. GAPDH was used as a loading control. Graph 
(right) shows normalised FRAS1 intensity. B. Representative immunofluorescence staining of FRAS1 
in skin tissue harvested from LM affected lesions (n=9) and normal skin (n=5). Graph (bottom) shows 
fluorescence normalised to cell number. * P < 0.05, unpaired T-Test. C. Representative western blot 
analysis of ADAMTS8 protein levels in normal and LM affected fibroblasts. Graph (right) shows 
normalised ADAMTS8 intensity. D. Representative immunofluorescence staining of ADAMTS8 in 
primary dermal fibroblasts from LM affected lesions and site-matched normal skin. E. Representative 
western blot analysis of α-SMA (ASMA) and ADAMTS8 in normal (N) or LM affected (n=3 biological 
replicates) (A) fibroblasts and normal fibroblasts transduced with either an empty vector control or 
an ADAMTS8 overexpression vector. GAPDH was used as a loading control. All data expressed as 
mean ± S.E.M. 
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1 TABLES 
Table 1. Clinical characteristics of patients with LM 
Patient Sex Age (years) Biopsy site 
1 Female 10 Thigh 
2 Female 12 Knee 
3 Male 8 Lower leg 
4 Male 17 Thigh 
5 Female 10 Thigh 
Clinical characteristics of patients with LM from whom biopsies were obtained. Primary dermal 
fibroblasts were isolated from affected (A) lesions and site-matched normal (N) regions. All patients 
were on methotrexate at time of harvest. 
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